☆ 4.7 Review

Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis

JOURNAL OF INFECTION (2022)

Related references

Note: Only part of the references are listed.

Review Immunology

COVID-19 in Immunocompromised Hosts: What We Know So Far

Monica Fung et al.

Summary: The COVID-19 pandemic caused by SARS-CoV-2 has led to significant morbidity and mortality globally. The impact of the disease on immunosuppressed patients, such as cancer patients and transplant recipients, remains unclear. Further research is needed to determine the risk of COVID-19 severity and death in immunocompromised patients.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang et al.

Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Urology & Nephrology

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients

Jose Jesus Broseta et al.

Summary: This study evaluated the humoral and cellular responses to mRNA SARS-CoV-2 vaccines in patients with kidney failure receiving maintenance dialysis. Results showed that a high proportion of patients developed humoral and cellular immune responses after vaccination, but older age and immunosuppressive treatment were associated with lower antibody levels.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Add to Collection

Review Microbiology

Immunologic Testing for SARS-CoV-2 Infection from the Antigen Perspective

Dandan Li et al.

Summary: SARS-CoV-2 infection stimulates antigen-specific antibody responses and multiple serologic tests have been developed for it. The S1 domain of the spike protein is considered more specific than other parts of the protein, and the receptor-binding domain as an antigen to test patient antibodies is more sensitive than the native N protein.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Review Infectious Diseases

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Susanne H. Hodgson et al.

Summary: The development of a vaccine for the novel coronavirus is crucial to prevent the spread of the pandemic and reduce disease mortality. The efficacy endpoint is protection against severe disease and death, but evaluating this in phase 3 clinical trials poses challenges.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Immunology

Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Robert Challen et al.

Summary: The study found that the mortality hazard ratio associated with infection with VOC-202012/1 compared with previously circulating variants was 1.64, indicating an increase in deaths from 2.5 to 4.1 per 1000 detected cases in comparatively low risk group of covid-19 patients in the community. This suggests that infection with VOC-202012/1 may lead to substantial additional mortality compared with previously circulating variants, impacting healthcare capacity planning and control policies.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Surgery

Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Ayelet Grupper et al.

Summary: Only 37.5% of transplant recipients developed a positive immune response to the Pfizer vaccine, with lower antibody levels, and factors associated with null immune response include older age, high-dose corticosteroids use, triple immunosuppression maintenance, and regimen with mycophenolate.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Oncology

Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors

J. Barriere et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

Ulf M. Geisen et al.

Summary: In this study, the efficacy and safety of anti-SARS-CoV-2 mRNA vaccines in immunosuppressed patients were compared with healthy controls. The results showed that all study participants developed antibodies, with lower IgG titres in patients compared to controls. Side effects were minimal and no disease flares were observed, demonstrating the efficiency and safety of mRNA vaccines in this cohort despite its small size.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies

Serre-Yu Wong et al.

GASTROENTEROLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

Peter J. Embi et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled et al.

Summary: The study investigated the safety and efficacy of BNT162b2 vaccine in heart transplant recipients, showing a low rate of adverse events and some individuals developing antibody responses. The presence of IgG anti-RBD antibodies was associated with neutralizing SARS-CoV-2 pseudo-virus, but certain immunosuppressive regimens may impact the odds of an antibody response. Further research is needed to determine the optimal observation period for antibody response in immunocompromised individuals.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

Add to Collection

Article Gastroenterology & Hepatology

Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients

Liane Rabinowich et al.

Summary: Liver transplant recipients showed significantly lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine, with less than half developing sufficient levels of antibodies and lower average antibody levels compared to healthy controls. Predictors for non-response included older age, renal function and immunosuppressive medications.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Oncology

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

Leticia Monin et al.

Summary: The study aimed to evaluate the safety and immunogenicity of the BNT162b2 vaccine in cancer patients. The results showed poor efficacy of a single vaccine dose in cancer patients, with significantly increased immunogenicity in solid cancer patients after a vaccine boost at day 21. Therefore, it is recommended to prioritize cancer patients for an early second dose on day 21.

LANCET ONCOLOGY (2021)

Add to Collection

Article Virology

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)

Johannes Korth et al.

Summary: Research has shown that renal transplant recipients have impaired immune response after receiving two doses of mRNA-based vaccine, with significantly lower antibody levels compared to healthy controls.

VIRUSES-BASEL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel-33 US Sites, January-March 2021

Tamara Pilishvili et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Article Medicine, General & Internal

Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

Thao T. Truong et al.

Summary: The study highlights the concern that persistent infection of SARS-CoV-2 in immunocompromised hosts may lead to mutation accumulation and emergence of strains that evade immune responses. There is a need to reassess infection control precautions and consider routine surveillance of mutations for their potential impact on viral transmission and immune escape.

EBIOMEDICINE (2021)

Add to Collection

Article Hematology

BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies

Katrin Herzog Tzarfati et al.

Summary: Patients with hematologic malignancies have a reduced immune response to the COVID-19 vaccine, with lower seropositivity rates and antibody titers, increasing their risk for severe infection.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Letter Surgery

Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients

Monica Miele et al.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2

Yolanda Braun-Moscovici et al.

Summary: The vast majority of patients with inflammatory rheumatic diseases developed a significant humoral response following the administration of the second dose of the Pfizer mRNA vaccine against SARS-CoV-2 virus. Only minor side effects were reported and no apparent impact on IRD activity was noted.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Rheumatology

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease

Rebecca H. Haberman et al.

Summary: The study found that patients with immune-mediated inflammatory diseases (IMIDs) on methotrexate treatment showed impaired humoral and cellular immune response to COVID-19 mRNA vaccines, while healthy subjects and IMID patients on biologic treatments demonstrated strong antibody responses. These results suggest that different strategies may need to be explored to enhance immunization efficacy for IMID patients on methotrexate treatment.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Hematology

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

Paola Ghione et al.

BLOOD (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients

Rene Schramm et al.

Summary: Ninety percent of cardiothoracic transplant patients showed no detectable immune response three weeks after receiving two doses of the BNT162b2 vaccine, in sharp contrast to the robust immune response seen in the control group.

CLINICAL RESEARCH IN CARDIOLOGY (2021)

Add to Collection

Article Infectious Diseases

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Yaniv Lustig et al.

Summary: The study found that healthcare workers vaccinated with Comirnaty showed reduced neutralising titres against the Gamma, Beta, and Delta variants, but the remaining neutralisation capacity may still be protective.

EUROSURVEILLANCE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications

Nabeel Khan et al.

Summary: The study found that full vaccination against SARS-CoV-2 has an effectiveness of approximately 80.4% in patients with inflammatory bowel disease who may be taking immunosuppressive medications.

GASTROENTEROLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Confronting the Delta Variant of SARS-CoV-2, Summer 2021

Carlos del Rio et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

Jan Havlin et al.

Summary: Transplant recipients showed weaker antibody response to mRNA COVID-19 vaccine compared to natural infection, with only a subset of patients demonstrating SARS-CoV-2 specific T-cell response. Further research is needed to identify the optimal vaccine type and schedule for immunocompromised transplant patients.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

Add to Collection

Article Urology & Nephrology

Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients

Dominique Bertrand et al.

Summary: Immunization with BNT162b2 appears to be more effective in HDPs, with the immune response in KTRs potentially influenced by immunosuppressive medications. Current vaccinal strategies for KTRs may not provide adequate protection against COVID-19 and may need further improvement.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Urology & Nephrology

Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

Clement Danthu et al.

Summary: The study shows that kidney transplant recipients have a strong inhibition of humoral response to COVID-19 vaccination due to immunosuppressant therapy, while patients undergoing hemodialysis have lower antibody levels. Factors such as age, serum albumin, and Kt/V can impact the level of antibody response.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

Ugur Sahin et al.

Summary: The BNT162b2 vaccine shows 95% efficacy in preventing COVID-19 by boosting neutralizing antibody titres and activating specific T cell responses. The vaccine-induced immune response is broad and stable, lasting for a prolonged period, providing good coverage against various SARS-CoV-2 variants.

NATURE (2021)

Add to Collection

Article Transplantation

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients

Nathalie Longlune et al.

Summary: For dialysis patients, the immunogenicity of anti-SARS-CoV-2 mRNA vaccine is high, and a two-dose vaccination is recommended with a possible third dose for non-responders. Patients awaiting kidney transplantation should be offered the vaccine before transplantation.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Add to Collection

Letter Medicine, General & Internal

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Nassim Kamar et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Rheumatology

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly

Emire Seyahi et al.

Summary: Patients with immune-mediated diseases had lower antibody response to the inactivated COVID-19 vaccine compared to healthy controls, especially those using immunosuppressive or immune-modulating drugs. Older age was also associated with lower antibody titers in both patient and control populations. Further studies are needed to determine if booster doses are necessary for these individuals.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Editorial Material Oncology

Serological response to COVID-19 vaccination in patients with cancer older than 80 years

Daniela Iacono et al.

JOURNAL OF GERIATRIC ONCOLOGY (2021)

Add to Collection

Article Hematology

Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

Kazimieras Maneikis et al.

Summary: Patients with haematological malignancies exhibit blunted and heterogeneous antibody responses after receiving the full course of BNT162b2 mRNA vaccination. Those actively treated with BTKIs, ruxolitinib, venetoclax, or anti-CD20 antibody therapies show the poorest responses, while patients who received tyrosine kinase inhibitors or various types of stem-cell transplantation had higher antibody responses. Severe breakthrough SARS-CoV-2 infections and deaths in fully vaccinated patients with haematological malignancies highlight the importance of continued adherence to non-pharmacological interventions and household vaccination.

LANCET HAEMATOLOGY (2021)

Add to Collection

Editorial Material Hematology

Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma

Sean H. Lim et al.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Mark W. Tenforde et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Review Oncology

COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies

Jason D. Goldman et al.

Summary: This review examines the impact of SARS-CoV-2 infection on mortality in populations with distinct forms of immunocompromise and discusses the immune dysregulation in COVID-19. It suggests that certain immunosuppressants may have varying effects on different populations, providing insights for the treatment of COVID-19.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Immunology

Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients

Hector Rincon-Arevalo et al.

Summary: Patients with kidney failure are at increased risk for SARS-CoV-2 infection, making effective vaccination critical. However, studies have found significantly impaired antibody responses to the BNT162b2 vaccine in kidney transplant recipients and dialysis patients, leading to insufficient immune responses.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Review Hematology

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

Abi Vijenthira et al.

Summary: The study found that patients receiving anti-CD20 therapy have poor responses to all types of vaccines, especially during treatment and at least 6 months post-treatment, with significantly lower SC rates compared to healthy and disease control groups. As time progresses, response to vaccination gradually improves, but even 12 months post-therapy, it may not reach the level of healthy controls.

BLOOD ADVANCES (2021)

Add to Collection

Article Rheumatology

Impaired Antibody Response to the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Christian Ammitzboll et al.

Summary: The study investigated the antibody response to the Pfizer-BioNTech BNT162b2 vaccine in rheumatic disease patients receiving immunosuppressive therapy, finding that 23% of patients could not mount a detectable serological response. Special attention is needed for patients receiving B cell-depleting therapy.

ACR OPEN RHEUMATOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Microbiology

Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients

Larry L. Luchsinger et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Victoria A. Avanzato et al.

CELL (2020)

Add to Collection

Letter Medicine, General & Internal

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Teresa Aydillo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Immunology

Accuracy of Administrative Code Data for the Surveillance of Healthcare-Associated Infections: A Systematic Review and Meta-Analysis

Michihiko Goto et al.

CLINICAL INFECTIOUS DISEASES (2014)

Add to Collection

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Add to Collection

Article Health Care Sciences & Services

Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews

JB Reitsma et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2005)

Add to Collection

Review Immunology

A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance

AD Harris et al.

CLINICAL INFECTIOUS DISEASES (2005)

Add to Collection

Article Medicine, General & Internal

Meta-analysis of observational studies in epidemiology - A proposal for reporting

DF Stroup et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.